Jaguar Gene Therapy
Elaine Kernbauer is an accomplished professional in clinical development and operations, currently serving as Senior Vice President of Clinical Development at Jaguar Gene Therapy since September 2024. Previously, Kernbauer held key leadership positions at Decibel Therapeutics as Vice President of Clinical Development Operations, and at Taysha Gene Therapies and AveXis, Inc. as Vice President of Clinical Operations. Kernbauer's extensive experience also includes director roles at Castle Creek Pharmaceuticals, and various managerial positions at Marathon Pharmaceuticals, AbbVie, Abbott Laboratories, and Rush University Medical Center. Kernbauer holds a Master of Science in Clinical Research & Regulatory Administration from Northwestern University and a Bachelor of Science in Molecular and Cellular Biology from the University of Illinois Urbana-Champaign.
This person is not in any teams
Jaguar Gene Therapy
Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. Led by the former AveXis leadership team and backed by Deerfield Management, a healthcare-specific investment firm, Jaguar brings streamlined R&D, manufacturing and clinical operations to accelerate development and potential approval of therapies for severe genetic diseases.